BOLTBolt Biotherapeutics, Inc.

NASDAQ · Healthcare · Large Cap · Mkt cap $1.19T · Vol 5.50M

$38.81

▲ +4.69% today

Fetching live price…

🏛️ Member of:S&P MidCap 400Russell 1000

God's Eye forensics

Accounting quality and solvency screens. Anything that can't be computed from available filings data is left blank rather than estimated.

Piotroski F-Score

5/5

5

5 of 5 financial-health checks passed (4 checks need data this provider doesn't publish).

Altman Z-Score

Insufficient data

—

Needs total assets, operating profit and debt — not published for this listing yet.

Beneish (earnings quality)

Insufficient data

—

The full manipulation model needs two years of receivables, depreciation and accrual data, which isn't published for this listing.

Scores are free. The criteria-by-criteria breakdown — exactly which checks this company failed — is part of DeepScreen Pro.

Fundamental breakdown — raw ratios are free · fetching live data — showing modeled estimates for now

P/E Ratio (TTM)

Modeled

21.4x

Fairly priced

Contextual insight — DeepScreen Pro

PEG Ratio

Modeled

1.19

Fairly valued

Contextual insight — DeepScreen Pro

P/S Ratio

Modeled

3.92x

Moderate

Contextual insight — DeepScreen Pro

P/B Ratio

Modeled

5.65x

Typical for the sector

Contextual insight — DeepScreen Pro

EV/Revenue

Modeled

3.75x

Low for an asset-light business

Contextual insight — DeepScreen Pro

EV/EBITDA

Modeled

15.0x

Fair

Contextual insight — DeepScreen Pro

ROE

Modeled

26.4%

Excellent shareholder returns

Contextual insight — DeepScreen Pro

ROA

Modeled

16.9%

Strong for asset-light

Contextual insight — DeepScreen Pro

ROCE

Modeled

24.9%

High-quality compounder

Contextual insight — DeepScreen Pro

Debt / Equity

Modeled

0.21x

Conservative balance sheet

Contextual insight — DeepScreen Pro

LT Debt / Equity

Modeled

0.17x

Very low structural debt

Contextual insight — DeepScreen Pro

Payout Ratio

Modeled

14%

Growth company — reinvesting most profit

Contextual insight — DeepScreen Pro

Operating Leverage

Modeled

2.33x

Good upside gearing

Contextual insight — DeepScreen Pro

Company financials

EPS (TTM): $1.81
Revenue (TTM): $304.4B
Net margin: 18.3%
EBITDA margin: 25%
Earnings growth: 18%
Dividend yield: 0.65%
Payout ratio: 14%
Debt / equity: 0.21x

Live data hasn't loaded yet — figures shown are DeepScreen's modeled estimates.

BOLT live news

LIVE

Loading live headlines…